Brokerages predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report $13.73 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings, with the highest sales estimate coming in at $15.48 million and the lowest estimate coming in at $10.51 million. Lexicon Pharmaceuticals posted sales of $33.05 million during the same quarter last year, which suggests a negative year over year growth rate of 58.5%. The firm is expected to issue its next quarterly earnings report on Thursday, February 28th.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year sales of $58.16 million for the current fiscal year, with estimates ranging from $54.00 million to $61.29 million. For the next year, analysts anticipate that the company will report sales of $176.51 million, with estimates ranging from $86.90 million to $262.56 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.07. The company had revenue of $6.90 million for the quarter, compared to analyst estimates of $12.56 million. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The firm’s revenue was down 74.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.29) EPS.
Several equities research analysts recently issued reports on LXRX shares. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, October 4th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 28th. Citigroup decreased their price target on shares of Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Gabelli reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Finally, Cowen reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $25.25.
Institutional investors and hedge funds have recently bought and sold shares of the business. Tocqueville Asset Management L.P. bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $164,000. Dynamic Technology Lab Private Ltd bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $205,000. MetLife Investment Advisors LLC grew its holdings in Lexicon Pharmaceuticals by 49.8% during the 3rd quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 11,862 shares during the last quarter. Tekla Capital Management LLC bought a new stake in Lexicon Pharmaceuticals during the 3rd quarter worth approximately $747,000. Finally, GSA Capital Partners LLP grew its holdings in Lexicon Pharmaceuticals by 321.7% during the 3rd quarter. GSA Capital Partners LLP now owns 74,586 shares of the biopharmaceutical company’s stock worth $796,000 after acquiring an additional 56,900 shares during the last quarter.
Shares of Lexicon Pharmaceuticals stock traded down $0.50 during midday trading on Wednesday, hitting $7.44. 533,618 shares of the company traded hands, compared to its average volume of 386,282. The firm has a market capitalization of $858.00 million, a PE ratio of -5.86 and a beta of 0.75. The company has a current ratio of 2.90, a quick ratio of 2.83 and a debt-to-equity ratio of 8.85. Lexicon Pharmaceuticals has a 12 month low of $7.04 and a 12 month high of $13.97.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: Hedge Funds
Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.